ClinicalTrials.gg
RecruitingNCT05477589SCRIPT-AMLUpdated Dec 19, 2024

Studying Conditioning Regimen In Pediatric Transplantation - AML , SCRIPT-AML

A Phase 3 interventional study of busulfan, cyclophosphamide and melphalan, BuCyMel and clofarabine, fludarabine and busulfan, CloFluBu in Acute Myeloid Leukemia (AML) in Remission and Stem Cell Transplantation, sponsored by Vastra Gotaland Region. Recruiting at 17 sites in 10 countries. Open to participants aged Up to 18 Years. Per ClinicalTrials.gov, last updated 2024-12-19.

Sponsored by Vastra Gotaland Region · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2022; still recruiting 4 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
170
Allocation
Randomized
Ages
Up to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 108 studies in Leukemia, Myeloid, Acute with a site in Belgium — 15 open to participants now, 29 under way, 14 of them phase 3. Leukemia, Myeloid, Acute · Belgium.

Planned enrollment
54th of 104
170 · median 176
Started
2022
with 5 others
Phase 3
48 of 108
8 open now
Primary completion
2029-12
later than 23 of 28 live
Registered
98th of 108
by date

Among the 108 studies in Leukemia, Myeloid, Acute with a site in Belgium, this one is the 54th largest by planned enrollment of the 104 interventional ones that give a count, is one of 6 that started in 2022, is one of 48 in phase 3, reaches primary completion later than 23 of the 28 other live ones, and was the 98th registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

15 of the 108 studies in Leukemia, Myeloid, Acute with a site in Belgium are open now. Recruiting first, the newest first:

9 more — sign in →

All 15 open studies →

A study can be open while its sites in Belgium have not opened yet or have stopped. Only those recruiting at a site in Belgium →

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: Up to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 108 studies in Leukemia, Myeloid, Acute with a site in Belgium, or all of them as a file.
02

Study summary

It is a randomized phase 3 study comparing two conditioning regimens in children with Acute Myeloid Leukemia, AML, undergoing allogenic stem cell transplantation. The primary aim is to investigate if a conditioning regimen containing one alkylator (Bu) combined with two antimetabolites (Clo and Flu) results in superior 2-year acute grade III to IV-free, chronic non-limited GvHD-free, relapse free survival than a conditioning regimen combining three alkylating agents (BuCyMel)

Read the detailed description

The study is designed as an open-label randomized phase III, multicenter superiority trial comparing two conditioning regimens CloFluBu and BuCyMel in children with acute myeloid leukemia (AML) with per-protocol indications to allogeneic hematopoietic stem cell transplantation with a myeloablative conditioning.

This study is composed of two parts - an interventional part that includes randomization, and an observational part. The interventional part is a phase III randomized, open label, multicenter parallel group trial comparing two conditioning regimens used in pediatric HCT: a three alkylator combination of busulfan, cyclophosphamide and melphalan (BuCyMel, standard arm) and a combination of clofarabine, fludarabine and busulfan in which two alkylators are replaced by antimetabolites (CloFluBu, experimental arm). The observational part will prospectively register outcome measures of transplantation in patients not fulfilling criteria for participation in the interventional part of the study (due to lack of complete remission, lack of matched sibling or unrelated donor, who were not recruited to a national upfront protocol or who decline participation in randomization) but consenting to registration of the data.

03

Conditions studied

  • Acute Myeloid Leukemia (AML) in Remission
  • Stem Cell Transplantation

Keywords

  • Leukemia
  • Leukemia, Myeloid, Acute
  • Neoplasms
  • Haematopoietic cell transplantation
  • Paediatric
04

Who can participate

Ages eligible
Up to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion criteria for randomization part of the study:

  • Age ≤18 years at time of initial AML, age ≤ 21 years at transplantation.
  • HCT is performed in a study participating center
  • All women of who have to have a negative pregnancy test within 2 weeks prior to the start of treatment.
  • Signed .
  • Any AML after initial treatment according to a defined international AML protocol. (NOPHO-DBH AML 2012/new protocol), or AML in first remission with transplant indications and treatment according to national AML protocol (NOPHO-DBH AML 2012 or new protocol).
  • In hematological remission, defined as:

\< 5 % leukemic blasts confirmed by flow cytometry (in patients with an informative leukemia associated immunophenotype) in a bone marrow sample taken ≤14 days prior to start of conditioning and no evidence of extramedullary disease, including in CNS and no leukemic blasts in the peripheral blood (verified by flow cytometry in case immature cells are detected in the peripheral blood differential).

-Patients must have a related or unrelated donor fulfilling any of the following criteria: HLA 10/10 allelic matched, identical, sibling BM donor or HLA 10/10 or 9/10 allelic matched related/unrelated BM or PBSC donor orHLA 5-6/6 unrelated or 6-7-8/8 unrelated Cord Blood (UCB)

Inclusion criteria for observation/registration only:

  • Diagnosis of acute myeloid leukemia
  • Indication for stem cell transplantation, as defined by primary treatment protocol or treating physician.
  • Age ≤18 years at time of initial AML, age ≤ 21 years at transplantation.
  • Not eligible for randomization, either due to lack of consent or not fulfilling inclusion criteria for interventional part of the study.
  • Signed informed consent to prospectively register follow-up data.

Exclusion criteria for the randomization part of the study :

  • Diagnosis of myelodysplastic syndrome (MDS).
  • Diagnosis of juvenile myelomonocytic leukemia (JMML).
  • History of previous (AML diagnosed as secondary cancer).
  • Known diagnosis of Fanconi anemia.
  • Prior autologous or allogeneic hematopoietic stem cell transplant.
  • Planned prophylactic DLI or other immunotherapeutic interventions after HCT that are not included in the upfront protocol, Planned anti-leukemic medication after HCT that are not included in the upfront protocol
  • Known intolerance to any of the chemotherapeutic drugs in the protocol.
  • Major organ failure precluding administration of planned chemotherapy.
  • Patients with uncontrolled bacterial, viral, or fungal infections (currently taking medication and with progression or no clinical improvement) at time of enrollment.
  • Severe concomitant disease that does not allow treatment according to the protocol at the investigator's discretion, e.g. malformation syndromes, cardiac malformations, metabolic disorders, renal impairment (\<30% of normal ), severe pulmonary, hepatic or cardiac impairment due to toxicity or infection.
  • / Lansky score \< 50%
  • Females who are pregnant (positive serum or urine βHCG) or breastfeeding.
  • Females of childbearing potential or men who have sexual contact with females of childbearing potential unwilling to use effective forms of or abstinence for one year after transplantation.
  • Subjects unwilling or unable to comply with the study procedures.

Exclusion criteria for the observational part of the study:

  • Diagnosis of Myelodysplastic syndrome (MDS).
  • Diagnosis of Juvenile myelomonocytic leukemia (JMML).
  • Age above 21 years at time of transplantation
  • No consent is given to prospectively register outcome data
  • Prior autologous or allogeneic hematopoietic stem cell transplant.
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
None (open label)
Enrollment
170 participants (estimated)

Study arms

  • Active comparator
    BuCyMel

    a combination of busulfan, cyclophosphamide and melphalan, conditioning regimen

    Drug: busulfan, cyclophosphamide and melphalan, BuCyMel

  • Experimental
    CloFluBu

    a combination of clofarabine, fludarabine and busulfan conditioning regimen

    Drug: clofarabine, fludarabine and busulfan, CloFluBu

Interventions

  • Drugbusulfan, cyclophosphamide and melphalan, BuCyMel

    a three alkylator combination of busulfan, cyclophosphamide and melphalan (BuCyMel, standard arm)

    Also known as: BuCyMel

  • Drugclofarabine, fludarabine and busulfan, CloFluBu

    combination of clofarabine, fludarabine and busulfan in which two alkylators are replaced by antimetabolites (CloFluBu, experimental arm)

    Also known as: CloFluBu

06

What researchers measure

Primary outcomes

  1. 2-year, acute grade III to IV-free, chronic non-limited GvH-free, relapse-free survival (GREF)

    To investigate if a conditioning regimen containing one alkylator (Bu) combined with two antimetabolites (Clo and Flu) results in superior 2-year acute grade III to IV-free, chronic non-limited GvHD-free, relapse free survival (GRFS) than a conditioning regimen combining three alkylating agents (BuCyMel)

    Time frame: 2 years

Secondary outcomes

  1. Neutrophil and platelet engraftment

    time to engraftment after stem cells transplantation, in all patients

    Time frame: 28 days post transplantation

  2. Primary graft failure

    The incidence of graft failure defined as neutrophil recovery by day +28 post transplantation

    Time frame: +28 days post transplantation

  3. Secondary graft failure

    The incidence of secondary graft failure

    Time frame: 2 years

  4. Cumulative incidence of relapse

    The incidence of cumulative incidence of relapse during the first two years after transplantation

    Time frame: 2 years

  5. The association between pre-HCT MRD and relapse

    % of remaining leukemic cells in the last bone marrow sample taken before start of conditioning

    Time frame: 2 years

  6. Cumulative incidence of transplant-related mortality

    The incidence of transplant-related mortality at 2 years

    Time frame: 2 years

  7. Disease-free survival

    Disease-free survival at 2 years

    Time frame: 2 years

  8. Overall survival

    Overall survival at 2 years

    Time frame: 2 years

  9. Immunological recovery

    Immunological recovery of CD3+ and CD4+ cells in peripheral blood

    Time frame: 2 years

  10. Incidence of grade II-IV and III-IV acute GVHD

    The incidence of acute GvHD

    Time frame: +180 days post transplantation

  11. Incidence of chronic GVHD

    The incidence of cGVHD

    Time frame: 2 years

  12. Incidence of grade ≥ 3 toxicity Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease

    The rates of grade ≥ 3 Sinusoidal Obstruction Syndrome/Veno-Occlusive Disease

    Time frame: + 100 days post transplantation

  13. Incidence of grade ≥ 3 toxicity Engraftment Syndrome (ES)

    The incidence of engraftment syndome

    Time frame: 2 years

  14. Incidence of grade ≥ 3 toxicity Transplant-associated thrombotic microangiopathy (TA-TMA)

    The incidence of TA-TMA

    Time frame: 2 years

  15. Incidence of grade ≥ 3 toxicity Hemorrhagic Cystitis (HC)

    The incidence of HC

    Time frame: 2 years

  16. Incidence of grade ≥ 3 infections

    The incidence of grade ≥ 3 infections of bacterial, viral and fungal origin

    Time frame: 2 years

  17. Health-Related Quality of Life, HRQoL.

    HRQoL will be measured at baseline and at certain intervals using the quality of life instrument EQ-5D-Y, (Youth)™which include 2 measurements, the descriptive scale ( i.g. the score 1 is no problems and 3 is a lot of problems) and the VAS scale( 1 is the worst health and 100 is the best health that day).

    Time frame: 2 years

  18. Transplant-associated hormonal and gonadal late effects

    the date of spontaneous puberty, date of spontaneous menarche for female patients and mean testicular volume for male patients, use of hormonal replacement therapy and use of fertility preservation

    Time frame: 2 years

  19. Nutritional status

    BMI in kg/m\^2 at baseline and post transplantation

    Time frame: 2 years

07

Study locations

6 of 17 sites recruiting
  • L'Hôpital Universitaire des Enfants Reine Fabiola (HUDERF)
    Brussels, 1020, Belgium
    Not yet recruiting
  • Cliniques Universitaires Saint-Luc (CUSL)
    Brussels, 1200, Belgium
    Not yet recruiting
    • Cécile Boulanger, MD, PhD · Contact
    • Cécile Boulanger, MD, PhD · Principal investigator
  • Department of Pediatric Hematology, Oncology and SCT, Ghent University Hospital
    Ghent, 9000, Belgium
    Not yet recruiting
  • University Hospital Leuven
    Leuven, 3000, Belgium
    Not yet recruiting
  • Centre Hospitalier Régional de la Citadelle (CHR)/CHU Liège
    Liège, 4000, Belgium
    Not yet recruiting
  • Paediatric Stem Cell Transplant and Immune Deficiency, Department of Pediatric and Adolescent Medicine, Section 4072, Rigshospitalet University Hospital of Copenhagen
    Copenhagen, DK-2100, Denmark
    Recruiting
  • Division of Hematology, Oncology, and Stem Cell Transplantation, The New Children's Hospital, Helsinki University Hospital
    Helsinki, FIN-00290, Finland
    Recruiting
  • Department of Pediatrics and Adolescent Medicine, Hong King Children's Hospital
    Hong Kong, Hong Kong
    Not yet recruiting
    • Daniel Cheuk, MD, PhD · Contactcheukkld@hku.hk
    • Daniel Cheuk, MD, PhD · Principal investigator
  • Schneider Children's Medical Center of Israel
    Petach Tikva, 4920235, Israel
    Not yet recruiting
    • Jerry Stein, MD,PhD · Contactjstein@clalit.org.il · 972-3-9253742
    • Jerry Stein, MD, PhD · Principal investigator
  • Vilnius University Hospital Santaros Klinikos Center for Pediatric Oncology and Hematology
    Vilnius, 08661, Lithuania
    Not yet recruiting
  • Princess Máxima Center for Pediatric Oncology
    Utrecht, 3584CS, Netherlands
    Recruiting
  • Department of Pediatric Hematology and Oncology, Oslo University HospitalOslo University Hospital
    Oslo, 0424, Norway
    Recruiting
    • Jochen Buechner, MD, PhD · Contactjocbuc@ous-hf.no · +4747416023
    • Jochen Buechner, MD, PhD · Principal investigator
  • Stemcelltransplant unit Hospital Niño Jesús
    Madrid, 28009, Spain
    Not yet recruiting
  • Queen Silvia Children's Hospital, Sahlgrenska University Hospital
    Gothenburg, 41685, Sweden
    Recruiting
  • Barncancercentrum, avdelning 64, Skane University Hospital
    Lund, SE- 221 85, Sweden
    Recruiting
  • Pediatric Hematology immunology and stem cell transplantation Astrid Lindgren children's Hospital Huddinge K86-88
    Stockholm, 141 86, Sweden
    Not yet recruiting
  • Childrens department for Blood and tumor diseases Uppsala University Hospital
    Uppsala, SE-751 85, Sweden
    Not yet recruiting
    • Natalja Jackmann, MD, PhD · Contactnatalja.jackmann@kbh.uu.se · +46 186119639
    • Natalja Jackmann, MD, PhD · Principal investigator
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2022 (actual). Primary completion is estimated for Dec 2029, 90 months after the start.

Of 78 non-industry phase 3 interventional studies under Leukemia, Myeloid, Acute, half reached primary completion within 87 months of starting (the median), counting those still running; a quarter within 66 and three quarters within 111. This study's planned 90 months is close to that.

Counting every sponsor, half of 121 studies reached it within 74 months; a quarter within 39 and three quarters within 99.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 13, 2022
First posted
Jul 28, 2022
StartActual
Jun 7, 2022
Primary completionEst.
Dec 31, 2029
CompletionEst.
Dec 31, 2031
Last update
Dec 19, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 19, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05477589
Responsible party
Sponsor
First posted
Jul 28, 2022
Start date
Jun 7, 2022
Primary completion
Dec 31, 2029 (estimated)
Completion
Dec 31, 2031 (estimated)
Last update
Dec 19, 2024

Study contacts

Karin Mellgren, Prof. MD
Contact
karin.mellgren@vgregion.se
+46 (0)31 3421000
Anna M Schröder Håkansson, RN
Contact
anna.schroder_hakansson@vgregion.se
+46 (0) 761141327
Karin Mellgren, Prof. MD
study chair · Sahlgrenska University Hospital
Birgitta Versluys, MD, Phd
principal investigator · Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion